Lumos Diagnostics (ASX:LDX) has reported encouraging real-world data from the use of its FebriDx point-of-care test across general practice, urgent care, and Acute Respiratory Infection hubs in the UK, showing the device can reduce unnecessary antibiotic use, improve patient satisfaction, and ease health system costs. …
Real-world evidence shows Lumos Diagnostics’ FebriDx cuts antibiotic use and delivers system savings
September 24, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 September
September 26, 2025 - - Podcast -
Waiting for any impact. Why the Albanese Government will hold fire on 'MFN'
September 26, 2025 - - Latest News -
Boehringer Ingelheim pushes for patient voices to lead policy reform
September 26, 2025 - - Latest News -
TGA consulting on the ongoing need for paper product information inserts
September 25, 2025 - - Latest News -
Gene therapy shows early promise in slowing Huntington’s Disease
September 25, 2025 - - Australian Biotech -
Federal minister to address AusBiotech International Conference as sector marks critical juncture
September 25, 2025 - - Australian Biotech -
Recce Pharmaceuticals begins patient dosing in pivotal diabetic foot infection trial
September 25, 2025 - - Australian Biotech